France · Funded startup

Who invested in Lys Therapeutics

2 rounds we have observed, with the one investor named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$5.9Mraised across 2 rounds since 2023, from 2 sources

Latest round
Grant, $5.9MSept 2025
Investors
1
See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

20242025
?Venture$5.9MGrant
First round
Venture
May 2023
Biggest round
$5.9M
Grant · Sept 2025
Between rounds
2.3 years
from the last two

The rounds

  1. Sept 2025
    Grant$5.9M1 returning

    Source recorded

  2. May 2023
    VentureAmount undisclosed1 new

    Source recorded

Founders and team

From Lys Therapeutics's own website: 1 on the team.

  • Werner KlingerHead of IT and data protection

Everyone who backed them

BpifranceGovernment2rounds

Missing a round, or an investor who was in one? Tell us.

Quick answers about Lys Therapeutics

Who invested in Lys Therapeutics?

Lys Therapeutics's investors include Bpifrance.

How much has Lys Therapeutics raised?

Lys Therapeutics has raised $5.9M across 2 rounds since 2023. One round did not disclose an amount, so the total is a floor.

When did Lys Therapeutics last raise?

Lys Therapeutics's most recent round was a Grant of $5.9M in Sept 2025.

What was Lys Therapeutics's biggest round?

Its most recent round, $5.9M in Sept 2025, is also its largest on record.

Who backed Lys Therapeutics first?

Lys Therapeutics's first round on record, in May 2023, was backed by Bpifrance.

What stage is Lys Therapeutics at?

Lys Therapeutics's latest named round is a Grant, in Sept 2025.

Where is Lys Therapeutics based?

Lys Therapeutics is based in France.

Companies like Lys Therapeutics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.